Discussion Board

Most Discussed: BABA SNOW SPY GL SNAP ASML CHWY TSLA ANCUF NAS:LSXMA

Topic	Replies	Activity
Great article. I would also like to note that Spinraza sales have been weak. Article Comments Biogen Is Suffering From Doubts About the Future	0	13 hours ago
I would also add that the weakening of the Japanese yen against the US dollar is also a risk. Article Comments Takeda Pharmaceutical: A Long-Term Cash Cow	0	13 hours ago
Nice work. It would be good to have a filter to show only those news that are relevant for the reader, e.g., all news related to stocks in a given por Article Comments Comprehensive Stock Market News Page: Your Centralized News Hub!	1	18 hours ago
Lot of demand got pulled forward during the Pandemic. EPS is still falling. No hurry to get into this one. Article Comments Thor Industries (THO): Climbing a Wall of Worry	1	1 day ago
The problem here, as you briefly point out, is the ownership and inadequacy of shareholder distributions. They are way over capitalized, hence the Sto Article Comments Why Ternium Is the World's Best Steel Company	3	1 day ago
These AI generated articles are just a waste of time in my mind. There was no value added whatsoever by this. Article Comments Enphase Energy (ENPH): A Comprehensive Valuation Analysis	0	1 day ago
Great feature, Don. Suggestion: Is it possible to seperate insider buys and sells. The former is far more important than the latter. It will make for Article Comments Visualize Stock Events with Our Enhanced Interactive Chart!	1	3 days ago
Nice Article. Loved it Article Comments Why Apple Is Missing From Berkshire Hathaway's Permanent Holdings List	0	Apr 25, 2024
A Guru Extraordinaire has left the stage. Article Comments Charlie Munger: A Look Back on His Legacy	0	Apr 24, 2024
Good article. Yes, I agree its a wide-moat company but looks a little over-valued given its low growth. Perhaps the refresh of it console will revive Article Comments A Cautious Perspective of Nintendo	0	Apr 24, 2024
I am finding it difficult to reconcile your view of outperform for the next 12 months with reality. Revenue has been flat for the last 3 years and the Article Comments Takeda Pharmaceutical: A Long-Term Cash Cow	2	Apr 24, 2024
Hello FUN. I'm back with a new username. After over 3 years of following you, I decided to promote myself from Apprentice to Trader. And if this comme Article Comments Kinross Gold Is Betting on the Great Bear Project	2	Apr 24, 2024
É uma excelente empresa e uma boa aposta. Article Comments Oracle Is Too Cheap	0	Apr 24, 2024
Greetings. Thank you for reading and liking this post. I will be glad for each of your subscriptions, which gives me more motivation to post high-qual Article Comments Takeda Pharmaceutical: A Long-Term Cash Cow	0	Apr 24, 2024
Will I be able to collect part of give away shares by Kroger to share holders at this time . Article Comments Albertsons Ends Fiscal Year with Modest Gains Amid Kroger Merger	0	Apr 23, 2024
Thanks for the article, Bernard! Article Comments TJX Companies: Own This Value Pick	1	Apr 22, 2024
The results show that upadacitinib (RINVOQ®; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission Article Comments Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis	0	Apr 18, 2024
what is the fair price? Article Comments AMD's Cost-Effective Strategy Is Intelligent, but the Valuation Is Troubling	1	Apr 18, 2024
Thanks for sharing your thoughts and insightful analysis.I've noticed that you were referring to Organon stock in the table of drug sales author's est Article Comments Biogen Is Suffering From Doubts About the Future	4	Apr 16, 2024
Great article FUN thank you!. Any guesses on what we might see from the gold and silver miners in the next couple weeks? What's your % of cash at? Article Comments Pan American Silver: Waiting for the Escobal Reopening	3	Apr 16, 2024

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Discussion Board

Great article. I would also like to note that Spinraza sales have been weak.

I would also add that the weakening of the Japanese yen against the US dollar is also a risk.

Nice work. It would be good to have a filter to show only those news that are relevant for the reader, e.g., all news related to stocks in a given por

Lot of demand got pulled forward during the Pandemic. EPS is still falling. No hurry to get into this one.

The problem here, as you briefly point out, is the ownership and inadequacy of shareholder distributions. They are way over capitalized, hence the Sto

These AI generated articles are just a waste of time in my mind. There was no value added whatsoever by this.

Great feature, Don. Suggestion: Is it possible to seperate insider buys and sells. The former is far more important than the latter. It will make for

Nice Article. Loved it

A Guru Extraordinaire has left the stage.

Good article. Yes, I agree its a wide-moat company but looks a little over-valued given its low growth. Perhaps the refresh of it console will revive

I am finding it difficult to reconcile your view of outperform for the next 12 months with reality. Revenue has been flat for the last 3 years and the

Hello FUN. I'm back with a new username. After over 3 years of following you, I decided to promote myself from Apprentice to Trader. And if this comme

&Eacute; uma excelente empresa e uma boa aposta.

Greetings. Thank you for reading and liking this post. I will be glad for each of your subscriptions, which gives me more motivation to post high-qual

Will I be able to collect part of give away shares by Kroger to share holders at this time .

Thanks for the article, Bernard!

The results show that upadacitinib (RINVOQ&reg;; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission

what is the fair price?

Thanks for sharing your thoughts and insightful analysis.I've noticed that you were referring to Organon stock in the table of drug sales author's est

Great article FUN thank you!. Any guesses on what we might see from the gold and silver miners in the next couple weeks? What's your % of cash at?

É uma excelente empresa e uma boa aposta.

The results show that upadacitinib (RINVOQ®; 15 mg) combined with a 26-week steroid tapering regimen achieved a higher rate of sustained remission